KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to -$216.0 million.

  • Pfizer's Tax Provisions fell 19230.77% to -$216.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.0 million, marking a year-over-year increase of 9253.73%. This contributed to the annual value of -$28.0 million for FY2024, which is 9748.88% up from last year.
  • Per Pfizer's latest filing, its Tax Provisions stood at -$216.0 million for Q3 2025, which was down 19230.77% from $141.0 million recorded in Q2 2025.
  • In the past 5 years, Pfizer's Tax Provisions ranged from a high of $1.6 billion in Q3 2022 and a low of -$964.0 million during Q4 2023
  • Over the past 5 years, Pfizer's median Tax Provisions value was $187.5 million (recorded in 2024), while the average stood at $232.2 million.
  • As far as peak fluctuations go, Pfizer's Tax Provisions skyrocketed by 20853.66% in 2022, and later crashed by 37078.65% in 2023.
  • Pfizer's Tax Provisions (Quarter) stood at -$328.0 million in 2021, then soared by 208.54% to $356.0 million in 2022, then plummeted by 323.31% to -$795.0 million in 2023, then skyrocketed by 129.43% to $234.0 million in 2024, then plummeted by 192.31% to -$216.0 million in 2025.
  • Its Tax Provisions stands at -$216.0 million for Q3 2025, versus $141.0 million for Q2 2025 and -$189.0 million for Q1 2025.